

Synthesis of New Trans Double-Bond Sphingolipid Analogues: $\Delta^{4,6}$ and Δ^6 Ceramides

Jiong Chun, Guoqing Li, Hoe-Sup Byun, and Robert Bittman*

Department of Chemistry and Biochemistry, Queens College of The City University of New York, Flushing, New York 11367-1597

robert_bittman@qc.edu

Received November 2, 2001


Unsaturation was introduced at $\Delta^{4,6}$ and Δ^6 of the sphingoid chain of naturally occurring ceramide **1** via a β -keto sulfoxide (**12**) and sulfone (**18**) derived from *N*-Boc-L-serine methyl ester acetamide (**9**), affording two novel ceramide analogues, (2*S*,3*R*)-2-octanoylamidodeca-(4*E*,6*E*)-diene-1,3-diol (**2**) and (2*S*,3*R*)-2-octanoylamidooctadec-(6*E*)-ene-1,3-diol (**3**). After C-alkylation of **12** with (*E*)-1-bromo-2-tetradecene (**8**), a trans double bond was installed by elimination of PhS(O)H, providing conjugated dienone oxazolidine **13**. Reaction of **18** with **8**, followed by desulfonation (Al(Hg)), afforded keto-oxazolidine **20**, which bears a (*E*)- Δ^6 double bond. The syntheses of analogues **2** and **3** from ketones **13** and **20**, respectively, were completed by the following sequence of reactions: diastereoselective reduction (NaBH₄/CeCl₃ or DIBAL-H), hydrolysis of the oxazolidine ring, liberation of the amino group, and installation of the *N*-amide group.

Introduction

Ceramide (*N*-acylsphingosine, **1**) is a long-chain aliphatic 2-amido-1,3-diol with a C(4),C(5)-trans double bond (Chart 1).¹ Considerable interest has been focused on its biochemistry and cell biology. Ceramide is a key intermediate in the biosynthesis of many other biologically important sphingolipids;² it has been implicated in many physiological events, including the regulation of cell growth and differentiation, inflammation, and programmed cell death (apoptosis).³ Ceramide is also a regulator of many biochemical and cellular responses to stress, such as exposure to heat, radiation, oxidative conditions, and chemotherapeutic agents.⁴

Ceramide as well as more complex sphingolipids are required for activation of membrane fusion of Semliki Forest virus (SFV) and other alphaviruses.⁵ The C(4)–C(5) trans double bond in the sphingoid base of naturally occurring **1** may be crucial for ceramide's capacity to modulate various fundamental biological functions.⁶ For example, it was shown that unnatural ceramide analogues having a cis C(4)–C(5) or a trans C(5)–C(6) double bond do not support fusion of SFV.⁶ Similarly, the

Chart 1



presence of the (*E*)-C(4)–C(5) double bond in the long-chain base of ceramide is important for the apoptotic response of **1**, since analogues that lack this double bond have reduced activity.^{7,8} An understanding of the structural biology of ceramide may be aided by the synthesis of its homologues, which can be tested as both substrates for ceramide-utilizing enzymes and as substitutes for naturally occurring ceramide in cell signaling events and other biological activities.

Synthetic routes to sphingosine and ceramide have been reviewed recently.⁹ In an extension of our previous studies on the (*E*)-C(5)–C(6),⁶ (*E*)-C(7)–C(8),¹⁰ and (*E*)-C(15)–C(16)¹⁰ double-bond analogues of ceramide, we report here a novel approach that allows the efficient

* To whom correspondence should be addressed. Tel: (718) 997-3279. Fax: (718) 997-3349.

(1) Karlsson, K.-A. *Chem. Phys. Lipids* **1970**, *5*, 6–43.
(2) (a) Hannun, Y. A. *Science* **1996**, *274*, 1855–1859. (b) Ariga, T.; Jarvis, W. D.; Yu, R. K. *J. Lipid Res.* **1998**, *39*, 1–16. (c) Perry, D. K.; Hannun, Y. A. *Biochim. Biophys. Acta* **1998**, *1436*, 233–243.

(3) (a) Dickson, R. C. *Annu. Rev. Biochem.* **1998**, *67*, 27–48. (b) Perry, D. K.; Bielawska, A.; Hannun, Y. A. In *Liposomes: Rational Design*; Janoff, A. S., Ed.; Marcel Dekker: New York, 1999; pp 145–157. (c) Shayman, J. A. *Kidney Int.* **2000**, *58*, 11–26.

(4) (a) Mathias, S.; Peña, L. A.; Kolesnick, R. N. *Biochem. J.* **1998**, *335*, 465–480. (b) Sawai, H.; Hannun, Y. A. *Chem. Phys. Lipids* **1999**, *102*, 141–147. (c) Hannun, Y. A.; Luberto, C. *Trends Cell Biol.* **2000**, *10*, 73–80. (d) Dobrowsky, R. T.; Kolesnick, R. N. *Methods Cell Biol.* **2001**, *66*, 135–165. (e) Ruvolo, P. P. *Leukemia* **2001**, *15*, 1153–1160.

(5) (a) Nieva, J. L.; Bron, R.; Corver, J.; Wilschut, J. *EMBO J.* **1994**, *13*, 2797–2804. (b) Wilschut, J.; Nieva, J. L.; Bron, R.; Moesby, L.; Reddy, K. C.; Bittman, R. *Mol. Membr. Biol.* **1995**, *12*, 143–149. (c) Corver, J.; Moesby, L.; Erukulla, R. K.; Reddy, K. C.; Bittman, R.; Wilschut, J. *J. Virol.* **1995**, *69*, 3220–3223.

(6) He, L.; Byun, H.-S.; Smith, J.; Wilschut, J.; Bittman, R. *J. Am. Chem. Soc.* **1999**, *121*, 3897–3903.


(7) Bielawska, A.; Crane, H. M.; Liotta, D.; Obeid, L. M.; Hannun, Y. A. *J. Biol. Chem.* **1993**, *268*, 26226–26232.

(8) Karasavvas, N.; Erukulla, R. K.; Bittman, R.; Lockshin, R.; Zakeri, Z. *Eur. J. Biochem.* **1996**, *236*, 729–737.

syntheses of two new unnatural analogues of ceramide in which a diene [(*E*)-C(4)–C(5) and (*E*)-C(6)–C(7), compound **2**; see Chart 1] and an (*E*)-C(6)–C(7) double bond are incorporated (compound **3**). Diene **2** may have a higher reactivity than ceramide **1** in mitochondria¹¹ by undergoing facilitated oxidation at C(3) to give an α,β -unsaturated ketone and hydrogen peroxide as the initial oxidation products, which eventually lead to apoptotic cell death. Although 4,6-sphingadienes have not been reported to occur naturally, it is of interest to note that 4,8-sphingadiene is the principal sphingoid backbone of the glucosylceramides found in soybean and wheat.¹² Its function is not known.


Results and Discussion

Since organosulfur compounds play important roles in the formation of carbon–carbon bonds,¹³ we decided to synthesize the novel analogues of ceramide **2** and **3** by use of the α -keto-sulfoxide and sulfone intermediates shown in the retrosynthetic plan (eq 1). Both of these intermediates are derived from the commercially available protected L-serine building block **9**.




Synthesis of Allylic Bromide 8. As shown in Scheme 1, allylic bromide **8** was synthesized via α,β -unsaturated ester **6**. The latter was obtained in 90% yield (*E/Z* ratio, ~18:1) by Horner–Wadsworth–Emmons (HWE) reaction of dodecanal (**4**) with the phosphonoacetate **5**. Reduction of ester **6** with DIBAL-H afforded allylic

Scheme 1. Synthesis of Allylic Bromide 8^a



^a Reagents and conditions: (a) (EtO)₂P(O)CH₂CO₂Et (**5**), LiBr, Et₃N, rt; (b) 3 equiv of DIBAL-H, THF, –78 to 0 °C; (c) NBS, Ph₃P, CH₂Cl₂, rt.

Scheme 2. Synthesis of Ketone 13^a



^a Reagents and conditions: (a) LDA, THF, –78 °C to rt; (b) **8**, K₂CO₃, DMF, rt, 3 d.

alcohol **7** in 90% yield. Treatment of allylic alcohol **7** with NBS via Mitsunobu reaction¹⁴ gave crude allylic bromide **8** in 93% yield.

Synthesis of Dienone 13. The synthesis of dienone **13** started with the protected serine-derived methyl ester **9**, which is readily prepared from L-serine in three high-yielding steps.¹⁵ Condensation of ester **9** with 2 equiv of the carbanion of methyl phenyl sulfoxide at –78 °C gave β -ketosulfoxide **11** in 70% yield (Scheme 2). Several methods were screened for alkylation of **11** with allylic bromide **8**. Cesium carbonate in DMF provided elimination product **13**, presumably via intermediate **12**. However, DBU in benzene was more convenient than Cs₂CO₃ in DMF, since no workup was required to obtain dienone **13**; the reaction mixture was simply passed through a pad of silica gel to remove the precipitate (DBU·HBr). Heating the filtrate in benzene for several hours afforded a mixture of two $\Delta^{4,6}$ -dienones, (4*E*,6*E*)-**13** and (4*Z*,6*E*)-**14**, in a ratio of ~4:1. We were able to avoid the formation of **14** by carrying out the reaction at room temperature, even though the reaction was slow.¹⁶ However, we noted that the optical rotation of **13** formed by using any of the above conditions was low, suggesting that racemization had occurred. The synthesis of chiral **13** was finally realized by using K₂CO₃¹⁷ in DMF. This two-step reaction was very efficient at room temperature, providing diene

(9) For reviews, see: (a) Byun, H.-S.; Bittman, R. In *Phospholipids Handbook*; Cevc, G., Ed.; Marcel Dekker: New York, 1993; pp 97–140. (b) Koskinen, P. M.; Koskinen, A. M. P. *Synthesis* **1998**, 8, 1075–1091. (c) Jung, K.-H.; Schmidt, R. R. In *Lipid Synthesis and Manufacture*; Gunstone, F. D., Ed.; Sheffield Academic Press: Sheffield, U.K.; CRC Press: Boca Raton, FL, 1999; pp 208–249. (d) Curfman, C.; Liotta, D. *Methods Enzymol.* **1999**, 311, 391–457. (e) Koskinen, P. M.; Koskinen, A. M. P. *Methods Enzymol.* **1999**, 311, 458–479.

(10) He, L.; Byun, H.-S.; Bittman, R. *J. Org. Chem.* **2000**, 65, 7627–7633.


(11) For recent evidence that some of the apoptotic properties of **1** are mediated by mitochondria, which oxidize ceramide to produce an allylic ketone, ultimately resulting in cell death, see: (a) Quillet-Mary, A.; Jaffrézou, J. P.; Mansat, V.; Bordier, C.; Naval, J.; Laurent, G. *J. Biol. Chem.* **1997**, 272, 21388–21395. (b) Ghafourifar, P.; Klein, S. D.; Schucht, O.; Schenk, U.; Pruschy, M.; Rocha, S.; Richter, C. *J. Biol. Chem.* **1999**, 274, 6080–6084. (c) Di Paola, M.; Cocco, T.; Lorusso, M. *Biochemistry* **2000**, 39, 6660–6668. (d) Corda, S.; Laplace, C.; Vicaut, E.; Duranteau, J. *Am. J. Respir. Cell Mol. Biol.* **2001**, 24, 762–768. (e) Radin, N. S. *Med. Hypotheses* **2001**, 57, 96–100.

(12) Sullards, M. C.; Lynch, D. V.; Merrill, A. H., Jr.; Adams, J. J. *Mass Spectrom.* **2000**, 35, 347–353.

(13) (a) Trost, B. M. *Chem. Rev.* **1978**, 78, 363–382. (b) Simpkins, N. S. In *Sulfones in Organic Synthesis*; Pergamon: Oxford, 1993. (c) For a preliminary communication on the use of sulfoxide and sulfone intermediates in the preparation of natural ceramide **1**, see: Chun, J.; Li, G.; Byun, H.-S.; Bittman, R. *Tetrahedron Lett.* **2002**, 43, 375–377.

(14) For a review of the Mitsunobu reaction, see: Hughes, D. L. *Org. React.* **1992**, 42, 335–656.

(15) Garner, P.; Park, J. M. *Org. Synth.* **1991**, 70, 18–27.


Scheme 3. Synthesis of Ketone **20**^a

^a Reagents and conditions: (a) *n*-BuLi, THF, $-78\text{ }^{\circ}\text{C}$; (b) DBU, benzene, rt; (c) Al(Hg), THF/H₂O (20/1), rt.


13 exclusively in 60% yield.¹⁸ These conditions not only avoided the difficult task of separating dienones **13** and **14**, which are formed together at elevated temperature, but also afforded **13** without racemization.

Synthesis of Ketone 20. Since α -ketosulfide **12** undergoes elimination even at room temperature it is not a suitable synthon for ketone **20**. Scheme 3 outlines the use of sulfone chemistry for the synthesis of **20**. Reaction of **9** with 2 equiv of the carbanion of methyl phenyl sulfone (**16**) at $-78\text{ }^{\circ}\text{C}$ gave β -ketosulfone **17** in 71% yield. Alkylation of **17** with allylic bromide **8** in the presence of a variety of bases was investigated. In Cs₂CO₃/DMF and DBU/DMF, dialkylation was the predominant reaction, giving **19** as the principal product. In DBU/benzene, monoalkylation of **17** was very efficient, giving **18/19** in a ratio of \sim 8:1. Sulfone intermediates **18** and **19** were readily separated by silica gel column chromatography.¹⁹ Desulfonylation of β -ketosulfone **18** with aluminum amalgam²⁰ afforded ketone **20** in 86% yield.

Synthesis of Ceramide Analogues 2 and 3. Several reducing agents were screened for the attempted dias-

Scheme 4. Synthesis of Ceramide Analogue **2**^a

^a Reagents and conditions: (a) NaBH₄, CeCl₃, MeOH or DIBAL-H, THF, -15 to $0\text{ }^{\circ}\text{C}$; (b) 1 M HCl, THF, $70\text{ }^{\circ}\text{C}$; (c) *p*-O₂NC₆H₄CO₂-C₇H₁₅-*n*, THF, rt.

Scheme 5. Synthesis of Ceramide Analogue **3**^a

^a Reagents and conditions: (a) (d) NaBH₄, MeOH, or DIBAL-H, THF, $-15\text{ }^{\circ}\text{C}$; (b) 1 M HCl, THF, $70\text{ }^{\circ}\text{C}$; (c) *p*-O₂NC₆H₄CO₂-C₇H₁₅-*n*, THF, rt.


tereoselective reduction of ketone **13** (Scheme 4).²¹ A higher erythro selectivity was observed with NaBH₄/CeCl₃ in MeOH or DIBAL-H in THF, which gave *erythro*-**23**/*threo*-**24** in a ratio of 4–5:1. However, the undesired *threo* diastereomer was formed as the major product with the other reducing agents we used; L-Selectride gave a \sim 1.3:1 ratio of *threo*/*erythro* isomers, and Red-Al gave **24:23** in 2:1 ratio). After diastereomers **23** and **24** were separated by column chromatography, acid hydrolysis of **23** (1 M HCl in THF, $70\text{ }^{\circ}\text{C}$) provided *D*-*erythro*-sphingosine **25**. Ceramide analogue **2** was obtained by *N*-acylation of sphingosine **25** with *p*-nitrophenyl octanoate.

Reduction of **20** with NaBH₄ or DIBAL-H gave alcohol **26**, but unfortunately the two diastereoisomers could not be isolated at this step (Scheme 5). Acid hydrolysis of **26** (1 M HCl in THF, $70\text{ }^{\circ}\text{C}$) provided crude sphingosine **27**. *N*-Acylation of sphingosine **27** with *p*-nitrophenyl oc-


(16) It is well known that elimination of a sulfoxide moiety from β -ketosulfoxides at high temperature affords (*E*)-enones; see: Trost, B. M.; Salzmann, T. N.; Hiroi, K. *J. Am. Chem. Soc.* **1978**, *98*, 4887–4902. Pyrolytic elimination of the sulfinyl moiety from an analogue of **12** that lacked the Δ^6 double bond gave the conjugated (*E*)- Δ^4 -3-keto product exclusively. When allylic β -protons are present in a β -ketosulfoxide (e.g., **12**), we observed that the elimination reaction proceeds even at room temperature, affording a conjugated dienone (e.g., **13**).

(17) Anhydrous K₂CO₃ in CH₃CN did not cause racemization of an oxazolidinone in an enone derived from a chiral β -ketophosphonate. See: Koskinen, A. M. P.; Koskinen, P. M. *Synlett* **1993**, 501–502.

(18) A less desirable route to dienone **13** is as follows. Treatment of sulfoxide **15** with LDA, followed by reaction of the α -sulfinyl carbanion with ester **9** at $-78\text{ }^{\circ}\text{C}$, gave the presumed β -ketosulfoxide intermediate **12**. After workup, the reaction mixture was dissolved in DMF and a small amount of K₂CO₃ was added, affording dienone **13** in \sim 32% overall yield.



(19) A less efficient approach to sulfone **18** is as follows. Reaction of methyl phenyl sulfone (**16**) with (*n*-BuLi) then with allylic bromide **8**, gave sulfone **21** in 50% yield, together with dialkylation byproduct **22**. Treatment of **21** with *n*-BuLi and reaction with ester **9** gave sulfone **18** in 40% yield.



(20) Troyansky, E. I. In *Encyclopedia for Organic Synthesis*; Paquette, L. A., Ed.; Wiley: Chichester, U.K., 1995; pp 150–153.

(21) (a) Hoffman, R. V.; Tao, J. *J. Org. Chem.* **1998**, *63*, 3979–3985. (b) Chun, J.; He, L.; Byun, H.-S.; Bittman, R. *J. Org. Chem.* **2000**, *65*, 7634–7640.

tanoate gave two diastereoisomers, which were separated by column chromatography. The erythro/threo ratio was about 6:1.

In summary, a simple and convenient method has been established for the regiospecific introduction of unsaturation (both at a single site and as a conjugated diene) into the sphingoid backbone of ceramide by employing organosulfur chemistry.

Experimental Section

General Information. Melting points were measured on a Hoover capillary melting point apparatus and are uncorrected. ^1H NMR and ^{13}C NMR spectra were recorded at 400 and 100 MHz on a Bruker spectrometer, respectively, and were referenced to the residual CHCl_3 at 7.24 (^1H) and 77.00 ppm (^{13}C). CDCl_3 was the only solvent used for the NMR analyses unless otherwise indicated. IR spectra were recorded on a Perkin-Elmer 1600-series FT-IR spectrophotometer, and CHCl_3 was used as the sole solvent. Optical rotations were measured in a 1.0-dm cell on a JASCO model DIP-140 digital polarimeter. High-resolution mass spectra were recorded at the University of California at Riverside. THF was distilled from sodium and benzophenone immediately before use. CH_2Cl_2 and DMF were dried over CaH_2 . Spectral-grade benzene was distilled from sodium wire. Flash chromatography and TLC were carried out with Merck silica gel 60 (230–400 ASTM mesh) and Merck 60F₂₅₄ (0.25-mm thick) sheets, respectively. NaBH_4 , L-Selectride, and *p*-nitrophenyl octanoate were purchased from Acros. Red-Al was purchased from Fluka. Ester **9** and diisopropylamine were purchased from Aldrich. Methyl phenyl sulfoxide (**10**) and methyl phenyl sulfone (**16**) were purchased from Alfa-Aesar.

Ethyl (E)-2-Tetradecenoate (6). To a nitrogen-flushed solution of 21.0 g (245 mmol) of LiBr in 200 mL of dry THF was injected 11.7 mL (13.2 g, 59 mmol) of $(\text{EtO})_2\text{P}(\text{O})\text{CH}_2\text{CO}_2\text{Et}$ (**5**) at rt. After the solution was stirred at rt for 10 min, 13.6 mL (98 mmol) of Et_3N was injected, and stirring was continued for 10 min. A solution of dodecanal (**4**, 9.0 g, 49 mmol) in 20 mL of dry THF was injected. The reaction mixture was stirred vigorously at rt until the full consumption of the aldehyde **4** was observed (TLC). The precipitate was removed by passing the reaction mixture through a pad of silica gel in a sintered glass funnel. The pad was washed with hexane/EtOAc 10:1. Concentration gave a pale yellow oil that was purified by column chromatography (hexane/EtOAc 20:1), providing 11.2 g (90%) of ester **6** as a colorless oil. The NMR data are in full accord with the literature data.²²

(E)-2-Tetradecen-1-ol (7). To a solution of 5.0 g (20 mmol) of ester **6** in 150 mL of dry THF was injected 40 mL of DIBAL-H (a 1.5 M solution in toluene, 60 mmol) at -78°C under argon. After 1 h, the solution was allowed to warm to 0°C . The reaction was quenched by slow addition of 5 mL of MeOH followed by 20 mL of cold 5% aqueous potassium sodium tartrate solution. The product was extracted with EtOAc (3×20 mL), and the combined organic layers were washed with brine (15 mL), dried (Na_2SO_4), and concentrated. Purification of the residue by column chromatography (hexane/EtOAc 4:1) gave 4.0 g (90%) of alcohol **7** as a colorless oil. The NMR data are in full accord with the literature data.²³

(E)-1-Bromo-2-tetradecene (8). To a solution of 2.12 g (10 mmol) of alcohol **7** and 2.75 g (1.05 mmol) of Ph_3P in 30 mL of dry CH_2Cl_2 was added 1.96 g (11 mmol) of NBS at 0°C under argon. The reaction mixture was stirred at 0°C for 1 h, allowed to warm to rt, and then stirred for 1 h. The mixture was diluted with 60 mL of hexane and passed through a pad of silica gel with suction to remove the precipitate of Ph_3PO . The filtrate was concentrated, and the resulting residue was dissolved in 60 mL of hexane and passed through a pad of silica gel to remove the precipitate of Ph_3PO again. Concentration gave

2.56 g (93%) of bromide **8** as a colorless oil: ^1H NMR δ 0.86 (t, 3H, $J = 6.5$ Hz), 1.10–1.50 (m, 18H), 2.04 (m, 2H), 3.92 (d, 2H, $J = 7.3$ Hz), 5.69 (m, 2H); ^{13}C NMR δ 14.1, 22.7, 28.8, 29.1, 29.3, 29.4, 29.57, 29.62, 29.64, 31.9, 32.1, 33.7, 126.2, 136.8.

N-tert-Butoxycarbonyl (4S)-4-[(Phenylsulfinyl)acetyl]-2,2-dimethyl-1,3-oxazolidine (11). To a solution of diisopropylamine (930 μL , 6.6 mmol) in 8 mL of THF was added 2.64 mL of *n*-butyllithium (a 2.5 M solution in hexane, 6.6 mmol) at -15°C under nitrogen. After the mixture was stirred at this temperature for 30 min, a solution of methyl phenyl sulfoxide (**10**, 841 mg, 6.0 mmol) in 5 mL of THF was added dropwise. The mixture was stirred at -15°C for 30 min and then chilled to -78°C . A solution of ester **9** (778 mg, 3.0 mmol) in 5 mL of THF was added dropwise. The solution was stirred at -78°C for 2 h and allowed to warm to rt overnight. After saturated aqueous NH_4Cl (10 mL) solution was added, the product was extracted with EtOAc, washed with brine, and dried (MgSO_4). Purification by column chromatography (hexane/EtOAc 1:4, R_f 0.72) gave 771 mg (70%) of **11** as a yellow solid: mp 82.5–85.0 $^\circ\text{C}$; IR 1710, 1385, 1170, 1090, 1055 cm^{-1} ; ^1H NMR (C_6D_6 , 70°C) δ 1.35 (s, 9H), 1.40 (s, 3H), 1.67 (s, 3H), 3.75 (m, 4H), 4.26 and 4.40 (two sets of s, 1H), 7.10 (m, 3H), 7.49 (m, 2H); the ^{13}C NMR spectrum was very complex because several diastereoisomers are present (see the Supporting Information); HR-MS (FAB, MH^+) calcd for m/z $\text{C}_{18}\text{H}_{26}\text{NO}_5\text{S}$ 368.1532, found 368.1516.

(3E)-Pentadecenyl Phenyl Sulfoxide (15). To a solution of diisopropylamine (930 μL , 6.6 mmol) in 8 mL of THF was added 2.64 mL of *n*-butyllithium (a 2.5 M solution in hexane, 6.6 mmol) at -15°C under nitrogen. After the mixture was stirred at this temperature for 30 min, a solution of PhS(O)-Me (**10**, 841 mg, 6.0 mmol) in 5 mL of THF was added dropwise. The mixture was stirred at -15°C for 30 min. A solution of bromide **8** (1.65 g, 6.0 mmol) in 5 mL of THF was added dropwise. The mixture was stirred at -15°C for 2 h and allowed to warm to rt overnight. Saturated aqueous NH_4Cl solution (10 mL) was added, and the product was extracted with EtOAc. The organic layer was washed with brine, dried (MgSO_4), and concentrated. Purification of the residue by column chromatography (hexane/EtOAc 3:2, R_f 0.72) gave 1.32 g (66%) of **15** as a colorless liquid: ^1H NMR δ 0.83 (t, 3H, $J = 6.6$ Hz), 1.10–1.40 (m, 18H), 1.92 (q, 2H, $J = 6.5$ Hz), 2.23 (dt, 1H, $J = 21.5$, 7.1 Hz), 2.41 (dt, 1H, $J = 22.3$, 7.5 Hz), 2.76 (q, 2H, $J = 8.0$ Hz), 5.30 (m, 1H), 5.49 (m, 1H), 7.45 (m, 3H), 7.58 (m, 2H); ^{13}C NMR δ 14.0, 22.6, 25.2, 29.0, 29.17, 29.24, 29.4, 29.5, 29.53, 29.56, 29.6, 31.8, 32.4, 56.9, 57.0, 123.9, 125.9, 129.1, 130.8, 133.5, 143.8.

N-tert-Butoxycarbonyl (4S)-4-[1'-Oxo-(2'E,4'E)-hexadecadienyl]-2,2-dimethyl-1,3-oxazolidine [(–)-13]. To a solution of β -ketosulfoxide **11** (370 mg, 1.0 mmol) in 4 mL of DMF was added K_2CO_3 (170 mg, 1.2 mmol) at rt. After the mixture was stirred at rt for 1 h under nitrogen, a solution of bromide **8** (275 mg, 1 mmol) in 2 mL of DMF was added. The mixture was stirred at rt for 3 days. Water (5 mL) was added, and the product was extracted with Et_2O (3×15 mL), washed with brine, and dried (MgSO_4). Concentration and purification by flash column chromatography (hexane/EtOAc 4:1, R_f 0.75) gave 261 mg (60%) of **13** as a white solid: mp 48.5–50.0 $^\circ\text{C}$; $[\alpha]_D^{25} -36.8^\circ$ (c 2.5, CHCl_3); IR 1700, 1385 cm^{-1} ; ^1H NMR (C_6D_6 , 70°C) δ 0.88 (t, 3H, $J = 7.0$ Hz), 1.10–1.30 (m, 18H), 1.39 (s, 9H), 1.55 (s, 3H), 1.82 (s, 3H), 1.92 (q, 2H, $J = 6.9$ Hz), 3.78–3.84 (m, 2H), 4.43 (br s, 1H), 5.81–5.89 (m, 1H), 5.95–6.01 (m, 1H), 6.23 (d, 1H, $J = 15.3$ Hz), 7.29 (dd, 1H, $J = 15.3$, 10.7 Hz); ^{13}C NMR (C_6D_6)²⁴ δ 14.1, 20.1, 28.4, 29.0, 29.1, 29.4, 29.5, 29.7, 32.2, 33.2, 33.3, (64.7) 65.0, (66.0) 66.3, (79.9) 80.0, (94.4) 95.3, 123.3 (124.4), (128.2) 129.2, (144.0) 144.2, (145.8) 146.4, 151.7 (152.2), (195.5) 196.0; HR-MS (FAB, MNa^+) calcd for m/z $\text{C}_{26}\text{H}_{45}\text{NO}_4\text{Na}$ 458.3247, found 458.3249.

N-tert-Butoxycarbonyl (4S)-4-[1'-oxo-(2'Z,4'E)-hexadecadienyl]-2,2-dimethyl-1,3-oxazolidine (14): ^1H NMR

(22) Popak, K.; Hesse, M. *Helv. Chim. Acta* **2001**, *84*, 180–186.

(23) Zhang, Z.-B.; Wang, Z.-M.; Wang, Y.-X.; Liu, H.-Q.; Lei, G.-X.; Shi, S. *J. Chem. Soc., Perkin Trans. 1* **2000**, 53–57.

(24) The oxazolidine system undergoes a dynamic equilibrium at ambient temperature.

(C₆D₆, 70 °C) δ 0.89 (t, 3H, J = 6.2 Hz), 1.10–1.30 (m, 16H), 1.39 (s, 9H), 1.52 (s, 3H), 1.50–1.60 (m, 2H), 1.81 (s, 3H), 2.81 (m, 2H), 3.77 (m, 2H), 4.27 (br s, 1H), 5.13 (d, 1H, J = 10.8 Hz), 5.50 (d, 1H, J = 17.4 Hz), 6.13 (m, 2H).

***N*-tert-Butoxycarbonyl (4S)-4-[1'-Hydroxy-(2'E,4'E)-hexadecadienyl]-2,2-dimethyl-1,3-oxazolidine [(–)-23]**. To a solution dienone **13** (325 mg, 0.75 mmol) in 15 mL of dry MeOH was added anhydrous CeCl₃ (61.5 mg, 0.25 mmol) at –15 °C. After the mixture was stirred for 10 min, NaBH₄ (32 mg, 0.85 mmol) was added. The temperature was gradually raised to 0 °C. After 2 h, water (20 mL) was added, and the product was extracted with Et₂O (3 × 25 mL), washed with brine, and dried (MgSO₄). Concentration and purification by column chromatography (hexane/EtOAc 4:1, R_f 0.45) gave 235 mg (72%) of **23** as a colorless oil: $[\alpha]_D^{25}$ –18.6° (c 1.5, CHCl₃); IR 1690, 1375 cm⁻¹; ¹H NMR (C₆D₆, 70 °C) δ 0.89 (t, 3H, J = 6.6 Hz), 1.28 (m, 18H), 1.38 (s, 9H), 1.43 (s, 3H), 1.61 (s, 3H), 2.02 (q, 2H, J = 6.8 Hz), 3.65 (m, 1H), 3.79 (br s, 1H), 3.94 (br s, 1H), 4.34 (m, 1H), 5.59–5.66 (m, 2H), 6.09 (m, 1H), 6.38 (m, 1H); ¹³C NMR (C₆D₆, 70 °C) δ 12.5, 14.1, 19.0, 22.9, 24.4, 26.8, 28.1, 28.4, 29.5, 29.59, 29.68, 29.71, 29.88, 29.99, 30.04, 32.3, 32.9, 33.1, 62.8, 65.0, 73.6, 80.2, 94.6, 128.7, 130.5, 131.78, 134.82; HR-MS (FAB, MNa⁺) calcd for m/z C₂₆H₄₇NO₄Na 460.3403, found 460.3419.

(2S,3R)-(4E,6E)-2-Octanoylamido-octadecadiene-1,3-diol [(–)-2]. A solution of 88 mg (0.2 mmol) of **23** in 4 mL of 1 M HCl and 4 mL of THF was heated at 70 °C with stirring for 10 h under argon. The reaction mixture was cooled to rt and neutralized with 1 M NaOH (4 mL). The product was extracted with EtOAc (3 × 10 mL), and the combined organic layers were washed with brine and dried (Na₂SO₄). Removal of the solvent provided crude sphingosine analogue **25** as a white solid, which was used in the next reaction without further purification. To a solution of **25** in 6 mL of dry THF was added 108 mg (0.40 mmol) of *p*-nitrophenyl octanoate at rt. The mixture was stirred for 48 h and concentrated. Purification by flash chromatography (CHCl₃/MeOH 9:1) afforded 51 mg (61%, two steps) of $\Delta^{4,6}$ -ceramide analogue **2** as a white solid: mp 69.0–71.0 °C; $[\alpha]_D^{25}$ –4.30° (c 2.2, CHCl₃); IR 1620, 1540, 1455 cm⁻¹; ¹H NMR δ 0.86 (t, 6H, J = 6.6 Hz), 1.10–1.40 (m, 26H), 1.60 (m, 2H), 2.05 (q, 2H, J = 7.1 Hz), 2.20 (t, 2H, J = 7.4 Hz), 3.69 (m, 1H), 3.90 (m, 2H), 4.37 (br s, 1H), 5.60 (dd, 1H, J = 15.3, 6.3 Hz), 5.73 (m, 1H), 6.00 (m, 1H), 6.27 (m, 2H); ¹³C NMR δ 14.05, 14.10, 22.6, 22.7, 25.8, 29.0, 29.15, 29.21, 29.3, 29.49, 29.59, 29.62, 29.65, 31.7, 31.9, 32.7, 36.8, 54.5, 62.5, 74.5, 128.9, 132.7, 136.7, 174.0; HR-MS (FAB, MNa⁺) calcd for m/z C₂₆H₄₉NO₃Na 446.3610, found 446.3598.

***N*-tert-Butoxycarbonyl (4S)-4-[(Phenylsulfonyl)acetyl]-2,2-dimethyl-1,3-oxazolidine [(–)-17]**. A solution of sulfone **16** (937 mg, 6.0 mmol) in 10 mL of THF was added 2.64 mL of *n*-butyllithium (a 2.5 M solution in hexane, 6.6 mmol) at –15 °C under nitrogen. The reaction mixture was stirred at –15 °C for 30 min and then chilled to –78 °C. A solution of ester **9** (778 mg, 3.0 mmol) in 5 mL of THF was added dropwise. The reaction mixture was stirred at –78 °C for 2 h and allowed to warm to rt overnight. Saturated aqueous NH₄Cl solution (10 mL) was added, and the product was extracted with EtOAc, washed with brine, and dried (MgSO₄). Purification by column chromatography (hexane/EtOAc 1:1, R_f 0.72) gave 817 mg (71%) of **17** as a white solid: mp 105–106 °C; $[\alpha]_D^{25}$ –93.2° (c 2.2, CHCl₃); ¹H NMR (C₆D₆, 70 °C) δ 1.33 (s, 9H), 1.45 (s, 3H), 1.58 (s, 3H), 3.90 (br s, 2H), 3.99 (d, 1H, J = 14.0 Hz), 4.15 (br s, 1H), 4.53 (br s, 1H), 6.99 (m, 3H), 7.78 (m, 2H); HR-MS (FAB, MH⁺) calcd for m/z C₁₈H₂₆NO₆S 384.1481, found 384.1487.

(3E)-Pentadecenyl Phenyl Sulfone (21). To a solution of sulfone **16** (780 mg, 5.0 mmol) in 5 mL of THF was added 2.4 mL of *n*-butyllithium (a 2.5 M solution in hexane, 6.0 mmol) at –78 °C under nitrogen. The solution was stirred at –78 °C for 30 min. A solution of bromide **8** (140 mg, 5.0 mmol) in 5 mL of THF was added dropwise. The mixture was stirred at –78 °C for 2 h and allowed to warm to rt overnight. After saturated aqueous NH₄Cl solution (10 mL) was added, the product was extracted with EtOAc, washed with brine, and

dried (MgSO₄). Purification by column chromatography (hexane/EtOAc 3:2, R_f 0.72) gave 175 mg (50%) of **21** as a colorless liquid: ¹H NMR δ 0.83 (t, 3H, J = 7.0 Hz), 1.10–1.40 (m, 18H), 1.87 (m, 2H), 2.35 (m, 2H), 3.08 (m, 2H), 5.22 (m, 1H), 5.41 (m, 1H), 7.51 (m, 2H), 7.61 (m, 1H), 7.86 (m, 2H); ¹³C NMR δ 14.0, 22.6, 25.8, 29.1, 29.2, 29.3, 29.47, 29.53, 31.8, 32.3, 56.0, 124.8, 128.0, 129.1, 133.5, 139.0.

***N*-tert-Butoxycarbonyl (4S)-4-[1'-Oxo-2'-phenylsulfonyl-(4'E)-hexadecenyl]-2,2-dimethyl-1,3-oxazolidine (18)**. To a solution of β -ketosulfone **17** (383 mg, 1.0 mmol) in 10 mL of benzene was added DBU (153 mg, 1.0 mmol) at rt. After the mixture was stirred at rt for 1 h under nitrogen, a solution of bromide **8** (275 mg, 1 mmol) in 5.0 mL of benzene was added dropwise. The reaction mixture was stirred at rt for 3 h and passed through a pad of silica gel to remove the precipitate (DBU-HBr). The pad was washed with benzene. Purification by column chromatography (hexane/EtOAc 4:1, R_f 0.70) gave 428 mg (74%) of **18** as a colorless liquid: IR 1732, 1698, 1390, 1360, 1315, 1175, 1145 cm⁻¹; ¹H NMR (C₆D₆, 70 °C) δ 0.96 (t, 3H, J = 7.0 Hz), 1.35 (m, 18H), 1.44 (s, 9H), 1.55 (s, 3H), 1.74 (s, 3H), 1.88 (m, 1H), 1.97 (m, 1H), 2.60–3.00 (m, 2H), 3.80–4.19 (m, 1H), 4.01–4.30 (m, 1.5H), 4.78–4.90 (m, 1H), 5.39 (br s, 1H), 5.46–5.49 (m, 1.5H), 7.05–7.17 (m, 3H), 7.23 (m, 1H), 8.04 (br s, 1H); HR-MS (FAB, MH⁺) calcd for m/z C₃₂H₅₂NO₆S 578.3515, found 578.3515.

***N*-tert-Butoxycarbonyl (4S)-4-[1'-Oxo-(4'E)-hexadecenyl]-2,2-dimethyl-1,3-oxazolidine [(–)-20]**. To a solution of ketosulfone **18** (290 mg, 0.50 mmol) in 25 mL of THF/H₂O 20/1 was added Al(Hg) (freshly prepared from aluminum foil; 135 mg, 5 mmol, 2% aqueous HgCl₂).²⁰ After the mixture was stirred at rt overnight, it was passed through a pad of silica gel with suction, which was washed with EtOAc. Concentration and purification by flash column chromatography (hexane/EtOAc 4:1, R_f 0.85) gave 186 mg (86%) of ketone **20** as a colorless oil: $[\alpha]_D^{25}$ –5.6° (c 2.8, CHCl₃); IR 1709, 1463, 1390, 1380, 1365, 1167 cm⁻¹; ¹H NMR (C₆D₆, 70 °C) δ 0.86 (t, 3H, J = 7.0 Hz), 1.29 (m, 18H), 1.38 (m, 9H), 1.47 (s, 3H), 1.75 (s, 3H), 1.96 (m, 2H), 2.30 (m, 2H), 2.39 (m, 2H), 3.69 (m, 2H), 4.16 (br s, 1H), 5.43 (m, 2H); ¹³C NMR (C₆D₆, 70 °C) δ 14.1, 23.0, 26.7, 28.4, 29.6, 29.7, 29.9, 30.0, 30.1, 32.3, 32.9, 65.6, 65.7, 80.2, 129.1, 131.8, 206.2; HR-MS (FAB, MNa⁺) calcd for m/z C₂₆H₄₇NO₄Na 460.3403, found 460.3393.

***N*-tert-Butoxycarbonyl (4S)-4-[1'-Hydroxy-(4'E)-hexadecenyl]-2,2-dimethyl-1,3-oxazolidine (26)**. To a solution of ketone **20** (65 mg, 0.15 mmol) in 4 mL of dry MeOH was added NaBH₄ (6.4 mg, 0.17 mmol) at –15 °C. The temperature was gradually raised to 0 °C. After 2 h, water (5 mL) was added, and the product was extracted with Et₂O (3 × 15 mL), washed with brine, dried (MgSO₄), and concentrated. Purification by column chromatography (hexane/EtOAc 4:1, R_f 0.45) gave 58 mg (88%) of **26** as a colorless oil: IR 1701, 1671, 1457, 1390, 1365 cm⁻¹; ¹H NMR (C₆D₆, 70 °C) δ 0.89 (t, 3H, J = 6.9 Hz), 1.22 (m, 20H), 1.30 (s, 9H), 1.47 (s, 3H), 1.63 (s, 3H), 2.00 (m, 2H), 2.20 (m, 1H), 2.34 (m, 1H), 3.61–3.69 (m, 2H), 3.84 (br s, 2H), 5.46–5.55 (m, 2H); ¹³C NMR (C₆D₆, 70 °C) δ 14.1, 23.0, 27.2, 28.4, 29.1, 29.6, 29.7, 30.0, 30.1, 32.3, 33.0, 62.7, 65.1, 80.3, 94.4, 130.5, 131.2.

(2S,3R)-(6E)-2-Octanoylamido-octadecene-1,3-diol [(–)-3]. A solution of 88 mg (0.2 mmol) of **26** in 4 mL of 1 M HCl and 4 mL of THF was heated at 70 °C with stirring for 10 h under argon. The reaction mixture was cooled to rt and neutralized with 1 M NaOH (4 mL). The product was extracted with EtOAc (3 × 10 mL), and the combined organic layers were washed with brine and dried (Na₂SO₄). Removal of the solvent provided crude sphingosine analogue **27** as a white solid, which was used in the next reaction without further purification. To a solution of **27** in 6 mL of dry THF was added 108 mg (0.40 mmol) of *p*-nitrophenyl octanoate at rt. The mixture was stirred for 48 h and then concentrated under reduced pressure. Purification by column chromatography (EtOAc) afforded 53 mg (63%, two steps) of Δ^6 -ceramide analogue **3** as a low-melting white solid: $[\alpha]_D^{25}$ –2.39° (c 2.2, CHCl₃); IR 1631, 1542 cm⁻¹; ¹H NMR δ 0.86 (t, 6H, J = 7.1 Hz), 1.10–1.40 (m, 26H), 1.52 (m, 2H), 1.62 (m, 2H), 1.93 (m, 2H), 2.07 (m, 2H), 2.21 (t, 2H, J = 7.7 Hz), 2.57 (br s, 2H), 3.78 (m, 2H), 3.88 (m, 1H),

3.96 (m, 1H), 5.38 (m, 2H), 6.20 (d, 1H, $J = 8.3$ Hz); ^{13}C NMR δ 14.05, 14.10, 22.5, 22.7, 25.8, 28.8, 29.0, 29.2, 29.4, 29.52, 29.53, 29.6, 29.7, 31.4, 31.7, 31.9, 32.6, 34.0, 36.9, 53.2, 65.4, 72.6, 129.1, 131.8, 174.1; HR-MS (DCI, MH^+) calcd for m/z $\text{C}_{26}\text{H}_{52}\text{NO}_3$ 426.3947, found 426.3952.

Acknowledgment. This work was supported by National Institutes of Health Grant No. HL 16660. We

thank the mass spectrometry facilities at the University of California at Riverside for the HR-MS data.

Supporting Information Available: Copies of ^1H and ^{13}C NMR spectra for compounds **2**, **3**, **11**, **13**, **15**, **17**, **18**, **20**, **21**, and **23**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

JO0162639